{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:29:45Z","timestamp":1777087785983,"version":"3.51.4"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cytomegalovirus\u2010specific T\u2010cell\u2010mediated immunity (CMV\u2010CMI) protects from CMV infection in allogeneic hematopoietic cell transplantation (allo\u2010HCT), but to date, there is no validated measure of CMV immunity for this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective, observational, pilot study, CMV T\u2010cell responses were evaluated monthly and at onset of graft\u2010versus\u2010host disease (GVHD) or CMV infection in CMV\u2010seropositive allo\u2010HCT recipients using a commercial flow cytometry assay, the CMV inSIGHT T\u2010Cell Immunity Panel (CMV\u2010TCIP). The primary endpoint was the time to first positive CMV\u2010TCIP, defined as percentage of interferon\u2010\u03b3\u2010producing CD4+ or CD8+ CMV\u2010specific T cells &gt;0.2%. Letermovir was prescribed from day +10 to \u2265100.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010eight allo\u2010HCT recipients were enrolled. The median time to first positive CMV\u2010TCIP result was earlier for CD4+ (60 days [interquartile range, IQR 33\u2012148]) than for CD8+ T cells (96 days [IQR 33\u2012155]) and longer for haploidentical and mismatched transplant recipients (77 and 96 days, respectively) than for matched donors (45 and 33 days, respectively). CD4+ and CD8+ CMV\u2010CMI recovery was sustained in 10\/10 (100%) and 10\/11 (91%) patients, respectively, without GVHD, whereas CD4+ and\/or CD8+ CMV\u2010CMI was lost in 4\/6 and 2\/6 patients, respectively, with GVHD requiring steroids. As a predictor of clinically significant CMV infection in patients with low\u2010level CMV reactivation, the sensitivity and negative predictive value of CMV\u2010TCIP were 90% and 87.5%, respectively, for CD4+ CMV\u2010TCIP and 66.7% and 62.5%, respectively, for CD8+ CMV\u2010TCIP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There was significant variability in time to CMV\u2010CMI recovery post\u2010HCT, with slower recovery after haploidentical and mismatched HCT. CD4+ CMV\u2010CMI may protect against CS\u2010CMVi, but immunity may be lost with GVHD diagnosis and treatment.\n<jats:boxed-text content-type=\"graphic\" position=\"anchor\"><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/tid14290-gra-0001-m.png\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:boxed-text><\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.14290","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T12:07:55Z","timestamp":1714997275000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dynamics of cytomegalovirus\u2010specific T\u2010cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9770-886X","authenticated-orcid":false,"given":"Samantha E.","family":"Jacobs","sequence":"first","affiliation":[{"name":"Department of Medicine Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uroosa","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akasha Barreto","family":"Vega","sequence":"additional","affiliation":[{"name":"The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lagdameo","sequence":"additional","affiliation":[{"name":"The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquelyn","family":"Callahan","sequence":"additional","affiliation":[{"name":"The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usha","family":"Govindarajulu","sequence":"additional","affiliation":[{"name":"Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Gitman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Molecular, and Cell\u2010Based Medicine Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Levine","sequence":"additional","affiliation":[{"name":"The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meenakshi","family":"Rana","sequence":"additional","affiliation":[{"name":"Department of Medicine Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alla","family":"Keyzner","sequence":"additional","affiliation":[{"name":"The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201011\u2010679639"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00034\u201008"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1210"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074744"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13786"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2018.01.002"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.018"},{"key":"e_1_2_10_9_1","unstructured":"Eurofins Viracor.CMV inSIGHT\u2122 T Cell Immunity Testing. Accessed October 23 2023.https:\/\/www.eurofins\u2010viracor.com\/clinical\/test\u2010menu\/30360\u2010cmv\u2010insight\u2010t\u2010cell\u2010immunity\/"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009396"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.03.003"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.001"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1620"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw668"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215943"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.01.008"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102002\u201011\u20103472"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010020\u20104787\u20104"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.05.001"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13866"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.08.002"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020088"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201010\u2010878918"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.261"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.14290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T11:53:05Z","timestamp":1718711585000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.14290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/tid.14290"],"URL":"https:\/\/doi.org\/10.1111\/tid.14290","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"2023-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14290"}}